University of New Mexico life sciences spin-out Tyrosine Pharma announces name change to Zocere.

Tyrosine Pharma, a spin-out of the University of New Mexico focused on developing stroke therapies, has announced a name change.

Now known as Zocere, the Albuquerque-based firm said the name change better reflected its development of drugs to combat stroke and other neurological conditions.

Zocere raised $250,000 in seed backing last year from angel investment coalition New Mexico Angels.

Wayne Laslie, president and chief exectuive, said: “We all know someone who has been struck down by stroke and how frustrating…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?